Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Dec;35(6):572-576.
doi: 10.37201/req/043.2022. Epub 2022 Oct 3.

Nosocomial meningitis caused by ESBL- and OXA-48-producing Klebsiella pneumoniae and treated with ceftazidime-avibactam. Report of one case and review of the literature

L B Valiente De Santis  1 , I Márquez Gómez, B Sobrino Díaz, I Pérez Camacho, C Mediavilla Gradolph, L F Caballero Martínez, F J Vicente Hernández, L Castelo Corral, M Delgado Fernández, A Plata Ciézar, J D Ruiz Mesa, J M Reguera Iglesias
Affiliations
Review

Nosocomial meningitis caused by ESBL- and OXA-48-producing Klebsiella pneumoniae and treated with ceftazidime-avibactam. Report of one case and review of the literature

L B Valiente De Santis et al. Rev Esp Quimioter. 2022 Dec.
No abstract available

Keywords: OXA-48; Postsurgical meningitis; carbapenemase-producing Klebsiella pneumoniae; ceftazidime-avibactam; nosocomial meningitis.

PubMed Disclaimer

Conflict of interest statement

All authors declare no conflict of interest.

References

    1. Balkan II, Aygün G, Aydın S, et al. Blood stream infections due to OXA-48-like carbapenemase-producing Enterobacteriaceae: treatment and survival. Int J Infect Dis. 2014;26:51-56. doi: 10.1016/j.ijid.2014.05.012 - DOI - PubMed
    1. Rodríguez-Baño J, Gutiérrez-Gutiérrez B, Machuca I, Pascual A. Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae. Clin Microbiol Rev. 2018;31(2):e00079-17. doi: 10.1128/CMR.00079-17 - DOI - PMC - PubMed
    1. Vena A, Giacobbe DR, Castaldo N, et al. Clinical Experience with Ceftazidime-Avibactam for the Treatment of Infections due to Multidrug-Resistant Gram-Negative Bacteria Other than Carbapenem-Resistant Enterobacterales. Antibiotics (Basel). 2020;9(2):71. doi: 10.3390/antibiotics9020071 - DOI - PMC - PubMed
    1. AEMPS , “Informe de Posicionamiento Terapéutico de ceftazidima/ avibactam (Zavicefta ® ),” pp. 1–11, 2018.
    1. Wilson GM, Fitzpatrick M, Walding K, et al. Meta-analysis of Clinical Outcomes Using Ceftazidime/Avibactam, Ceftolozane/Tazobactam, and Meropenem/Vaborbactam for the Treatment of Multidrug-Resistant Gram-Negative Infections. Open Forum Infect Dis. 2021;8(2):ofaa651. doi: 10.1093/ofid/ofaa651 - DOI - PMC - PubMed